At the request of the Editors, SAGE Publishing and the Authors, the following article has been retracted. Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer - real world claim data, Henry WC Leung, Agnes LF Chan, Shyh-Yau Wang, Journal of Oncology Pharmacy Practice, first published online January 31st 2018 DOI: 10.1177/1078155218755548 The authors notified the Editor and SAGE that some of the data included in this paper is incorrect and therefore results may be unreliable. For this reason, the article has been retracted. The authors of this paper are currently reviewing their data and the journal welcomes the authors to submit a new paper with revised, corrected data for consideration.